Skip to content
Open access · OA via OpenAlex

Pegaptanib for Neovascular Age-Related Macular Degeneration

Evangelos S. Gragoudas, Anthony P. Adamis, Emmett T. Cunningham, Matthew Feinsod, David R. Guyer

New England Journal of Medicine · 2004 · ▲ 2,335 citations

Abstract

BACKGROUND: Pegaptanib, an anti-vascular endothelial growth factor therapy, was evaluated in the treatment of neovascular age-related macular degeneration. METHODS: We conducted two concurrent, prospective, randomized, double-blind, multicenter, dose-ranging, controlled clinical trials using broad entry criteria. Intravitreous injection into one eye per patient of pegaptanib (at a dose of 0.3 mg, 1.0 mg, or 3.0 mg) or sham injections were administered every 6 weeks over a period of 48 weeks. The primary end point was the proportion of patients who had lost fewer than 15 letters of visual acuity at 54 weeks. RESULTS: In the combined analysis of the primary end point (for a total of 1186 patients), efficacy was demonstrated, without a dose-response relationship, for all three doses of pegaptanib (P<0.001 for the comparison of 0.3 mg with sham injection; P<0.001 for the comparison of 1.0 mg with sham injection; and P=0.03 for the comparison of 3.0 mg with sham injection). In the group given pegaptanib at 0.3 mg, 70 percent of patients lost fewer than 15 letters of visual acuity, as compared with 55 percent among the controls (P<0.001). The risk of severe loss of visual acuity (loss of 30 letters or more) was reduced from 22 percent in the sham-injection group to 10 percent in the group receiving 0.3 mg of pegaptanib (P<0.001). More patients receiving pegaptanib (0.3 mg), as compared with sham injection, maintained their visual acuity or gained acuity (33 percent vs. 23 percent; P=0.003). As early as six weeks after beginning therapy with the study drug, and at all subsequent points, the mean visual acuity among patients receiving 0.3 mg of pegaptanib was better than in those receiving sham injections (P<0.002). Among the adverse events that occurred, endophthalmitis (in 1.3 percent of patients), traumatic injury to the lens (in 0.7 percent), and retinal detachment (in 0.6 percent) were the most serious and required vigilance. These events were associated with a severe loss of visual acuity in 0.1 percent of patients. CONCLUSIONS: Pegaptanib appears to be an effective therapy for neovascular age-related macular degeneration. Its long-term safety is not known.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1056/nejmoa042760
Canonical
link ↗
Fetched
2026-10-19 MST

Cite this

APA
Gragoudas, E.S., Adamis, A.P., Cunningham, E.T., Feinsod, M., &amp; Guyer, D.R. (2004). Pegaptanib for Neovascular Age-Related Macular Degeneration. <em>New England Journal of Medicine</em>. https://doi.org/10.1056/nejmoa042760
Vancouver
Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for Neovascular Age-Related Macular Degeneration. New England Journal of Medicine. 2004. doi:10.1056/nejmoa042760.
BibTeX
@article{evangelos2004Pegapt, title = {Pegaptanib for Neovascular Age-Related Macular Degeneration}, author = {Evangelos S. Gragoudas and Anthony P. Adamis and Emmett T. Cunningham and Matthew Feinsod and David R. Guyer}, journal = {New England Journal of Medicine}, year = {2004}, doi = {10.1056/nejmoa042760}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings